Mithra Will Propose Christiane Malcorps as new Independent Board Member / Phase III Clinical Study for Estelle® in us Launched With First Randomized Patient

Liège, Belgium, 23rd September 2016 –Today, Mithra announces that Christiane Malcorps will be proposed as a new member of Mithra’s Board of Directors (Mithra SA) during the next Shareholders meeting. She also is appointed as member of the Board of Mithra’s CDMO (Development and production center).

Liège, Belgium 23rd September 2016 – Mithra announces today that the first patient has been randomized in the American Phase III clinical trials for its Estetrol-based product candidate Estelle® (E4/DRSP). The enrollment of this first patient marks the official launch of the Estelle® (E4/DRSP) Phase III clinical trial in United States. With this, the Phase III is fully in line with the timing and objectives announced in the Prospectus.

Download the press release